博瑞医药(688166) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was CNY 340,133,145.78, representing an increase of 11.54% compared to the same period last year[4]. - The net profit attributable to shareholders decreased by 9.47% to CNY 64,069,918.71, while the net profit after deducting non-recurring gains and losses decreased by 7.89% to CNY 64,214,448.31[4]. - Total operating revenue for Q1 2024 reached RMB 340,133,145.78, an increase of 11.5% compared to RMB 304,937,396.25 in Q1 2023[19]. - Net profit for Q1 2024 was RMB 70,586,962.95, a decrease of 6.7% compared to RMB 75,605,622.55 in Q1 2023[19]. - Total comprehensive income for Q1 2024 was ¥59.52 million, compared to ¥66.04 million in Q1 2023, reflecting a decrease of 9.8%[48]. Cash Flow and Assets - The net cash flow from operating activities surged by 492.42% to CNY 148,461,770.92, primarily due to an increase in received payments compared to the previous year[5]. - Cash and cash equivalents at the end of Q1 2024 were approximately ¥970.96 million, slightly down from ¥989.27 million at the end of Q1 2023[51]. - The company's cash and cash equivalents were CNY 984.47 million, down from CNY 998.05 million at the end of 2023[44]. - As of March 31, 2024, the company's total assets amounted to CNY 5.09 billion, compared to CNY 5.03 billion at the end of 2023[45]. - The company's fixed assets increased to CNY 825.91 million from CNY 718.12 million year-on-year[45]. Research and Development - Research and development expenses totaled CNY 65,047,828.56, an increase of 33.68%, accounting for 19.12% of operating revenue, up by 3.16 percentage points[4]. - The company is committed to a "R&D-driven" strategy, focusing on innovative drugs and inhalation formulations[5]. - The company completed BE trials for the inhaled form of Budesonide and is progressing with other inhalation products[56]. - The company has received ethical approval for Phase II clinical trials for BGM0504 injection for weight loss and type 2 diabetes treatment[56]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 11,553[23]. - Major shareholder Yuan Jiandong holds 26.87% of the company's shares, while Zhong Weifang holds 5.34%[26]. - The company has not reported any changes in the participation of major shareholders in margin trading or securities lending activities[26]. Market and Product Development - The company submitted 9 new domestic patent applications and obtained 6 new domestic patent authorizations in Q1 2024, bringing the total patent applications to 462[12]. - The construction of the Taixing raw material and formulation production base (Phase I) has been completed and accepted, while Phase II is undergoing environmental acceptance testing[13]. - The company received drug registration certificates for several products, including the injection of Carboprost Tromethamine and approvals for various raw materials in both domestic and international markets[29]. - The company plans to continue expanding its market presence and investing in new technologies[24]. Operating Costs and Revenue Breakdown - Total operating costs for Q1 2024 were RMB 267,341,183.31, up 16.6% from RMB 229,202,715.92 in Q1 2023[19]. - Product sales revenue reached CNY 303.57 million, up 13.30% year-on-year, with raw material drug revenue at CNY 246.99 million (up 11.67%) and formulation product revenue at CNY 56.58 million (up 21.02%)[27]. - Technical revenue decreased by 34.90% year-on-year to CNY 16.04 million, while equity sharing revenue increased by 10.49% to CNY 13.66 million[27]. - The company experienced a loss in investment income of RMB 4,545,946.74, compared to a loss of RMB 1,552,441.38 in the previous year[19]. Earnings Per Share - Basic and diluted earnings per share for Q1 2024 were both ¥0.15, down from ¥0.17 in Q1 2023[48].